Takis Biotech

Innovation in the Age of Coronavirus

The COVID-19 pandemic and its evolving aftermath are reshaping the world around us, and myriad Long Island forces – large and small, corporate and nonprofit, industrial and academic – have risen to the challenge. Innovate Long Island presents Innovation in the Age of Coronavirus as a real-time journal of this region’s resourceful response to the greatest global challenge since World War II. Stay healthy, dear readers.   Suffolk EOC offers federal funds for rent, food…


Gains on two fronts: Same-day test, virus ‘neutralizer’

By GREGORY ZELLER // An ambitious Long Island biotech is reporting exciting progress in a two-front battle against the raging novel coronavirus. Stony Brook-based Applied DNA Sciences on Tuesday announced that it has applied for FDA approval of its Linea COVID-19 diagnostic kit, which detects SARS-CoV-2 – the novel coronavirus that causes the COVID-19 disease – with same-day results. The announcement comes one day after Applied DNA and Italian biopharma Takis Biotech said the first…


LI biotech speeds COVID-19 vaccine candidates to Italy

By GREGORY ZELLER // With preliminary lab tests looking good, an innovative Long Island biotech is rushing a quintet of potential COVID-19 vaccines overseas. Stony Brook-based Applied DNA Sciences announced Wednesday that it has completed “design qualifications” and shipped five COVID-19 vaccine candidates to Italian biopharma Takis Biotech, a frequent collaborator working closely with Applied DNA to counter the coronavirus. The vaccine candidates were produced using the Stony Brook biotech’s proprietary, polymerase chain reaction-based LinearDNA…


Island firm speeds coronavirus vaccines toward tests

By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the Stony Brook-based biotech’s unique DNA-manufacturing abilities, Rome, Italy-based Takis Biotech will test potential vaccines against the coronavirus (now going by COVID-19) in laboratory mice, on a large scale. Applied DNA expects delivery of four DNA-based “preclinical vaccine candidates” from Takis this month, and “within weeks” will…


No. 477: In which the Suffolk IDA incentivizes and the double helix debuts – plus, sticky buns for all!

  Just a word or two: Welcome to Friday, dear readers, as we wrap up another busy workweek and look forward to another well-earned weekend. It’s Feb. 21 out there, and before we begin, please speak up – today is International Mother Language Day, the U.N.’s multicultural salute to linguistic diversity. Going to extremes: Today is also National Grain-Free Day (a big one for the low-carb set) and National Sticky Buns Day (not so much)….


Applied DNA to speed up coronavirus countermeasures

By GREGORY ZELLER // Look out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will now work on a “linear DNA” vaccine against the dreaded Wuhan, China-based illness that’s…


‘Linear DNA’ combo shows punch in cancer fight

By GREGORY ZELLER // Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic cancer vaccines. It might be catching up. On Thursday, LineaRX announced that both vaccines – each produced in “linear DNA” form…